486 results on '"Lister, T Andrew"'
Search Results
2. Supplementary Table 1 from Chemosensitization of B-Cell Lymphomas by Methylseleninic Acid Involves Nuclear Factor-κB Inhibition and the Rapid Generation of Other Selenium Species
3. Data from AML1/ETO Proteins Control POU4F1/BRN3A Expression and Function in t(8;21) Acute Myeloid Leukemia
4. Supplementary Table 1 from AML1/ETO Proteins Control POU4F1/BRN3A Expression and Function in t(8;21) Acute Myeloid Leukemia
5. Chronic Lymphocytic Leukemia : Diagnosis and Management
6. Clinical Sensitivity to Anthracyclines in PH/BCR+ Acute Lymphoblastic Leukemia
7. Microdeletions Are a General Feature of Adult and Adolescent Acute Lymphoblastic Leukemia: Unexpected Similarities with Pediatric Disease
8. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
9. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction
10. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
11. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
12. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy
13. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
14. Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
15. Lymphoma Metastasizing to the Pituitary: An Unusual Presentation of a Treatable Disease
16. Edward Shelton Henderson MD Chemotherapy Pioneer July 19, 1932 to June 24, 2020
17. Mutation of CEBPA in familial acute myeloid leukemia
18. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
19. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
20. A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy
21. Contributors
22. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
23. Historical prospect for the concept of primary extranodal lymphoma
24. Preface
25. Follicular Lymphoma
26. Contributors
27. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
28. The clinical course of follicular lymphoma
29. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms
30. Number of CD4+ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome
31. Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkinʼs Lymphoma
32. Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease
33. Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity
34. Improved Survival for Patients With Follicular Lymphoma
35. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3
36. Brief Report: Mutation of CEBPA in Familial Acute Myeloid Leukemia
37. Serum Selenium in Lymphoma
38. Clinical Sensitivity to Anthracyclines in PH/BCR+ Acute Lymphoblastic Leukemia
39. Who Should Receive Myeloablative Therapy for Lymphoma?
40. Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance
41. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
42. High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
43. Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia
44. JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements
45. The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction
46. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
47. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
48. Detection of Chromosome Abnormalities Pre–High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin’s Lymphoma
49. Long-term outcome of patients surviving for more than ten years following treatment for acute leukaemia
50. Frequency of the Bcl-2/IgH Rearrangement in Normal Individuals: Implications for the Monitoring of Disease in Patients With Follicular Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.